ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Acetaminophen

Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.

Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.

Drug pageAcetaminophen: every studyMany companies study it; this page follows only the 123 they lead. All 662 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005123 company-led studies, 1 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only390 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
GlaxoSmithKline240 open or runningphase 4since Feb 18, 2010Jun 2, 2006none ahead
Keenova Therapeuticsits history only110 open or runningphase 4since Feb 5, 2016Nov 14, 2006none ahead
Allodynic Therapeuticsits history only60 open or runningphase 3since Jun 8, 2017Feb 17, 2017none ahead
Novartisits history only60 open or runningphase 4since Jun 19, 2007Jan 29, 2007none ahead
Sanofiits history only41 open or runningphase 3since Feb 12, 2007Feb 12, 2007May 17, 2027phase 2 · NCT06647407
Sun Pharmaceutical Industriesits history only40 open or runningno phasesince Feb 18, 2010Feb 18, 2010none ahead
AFT Pharmaceuticalsits history only30 open or runningphase 3since Aug 16, 2011Aug 16, 2011none ahead
Nevakarits history only30 open or runningphase 2since Jul 8, 2019Jul 8, 2019none ahead
Angelini Pharmaits history only20 open or runningphase 2since Apr 9, 2015Apr 9, 2015none ahead

Also a collaborator on its studies: Nevakar Injectables, Cross, Cross Research, Premier Research Group, Aptuit, MDS Pharma Services and PriCara, Unit of Ortho-McNeil.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Jun 2, 2006.

  1. Mar 4, 2010Phase 4 study in Osteoarthritis, KneeNCT01105936 · 31 enrolled · Spain
  2. Jan 12, 2011Phase 2 study in Common ColdNCT01277081 · 200 enrolled · United Kingdom
  3. Jun 23, 20113 phase 1 studiesNCT01568749, NCT01551836, NCT01381640
  4. Nov 3, 2011Phase 4 study in Common ColdNCT01466348 · 72 enrolled · United Kingdom
  5. Nov 17, 20112 phase 1 studiesNCT01592227, NCT01476189
  6. Feb 23, 20123 phase 1 studiesNCT01551797, NCT01540734, NCT01540721
  7. Sep 13, 2012Phase 3 study in Common ColdNCT01686646 · 240 enrolled · United Kingdom
  8. Dec 6, 2012Phase 1 study in FeverNCT01767428 · 30 enrolled
  9. Mar 28, 2013Phase 4 study in Gastrointestinal Mucosal DamageNCT01822665 · 28 enrolled · United States
  10. Apr 25, 2013Phase 3 study in PainNCT01842633 · 365 enrolled · United States
  11. Dec 4, 2014Phase 3 study in PainNCT02311881 · 960 enrolled · United States
  12. Feb 1, 20162 phase 3 studies in Respiratory Tract InfectionsNCT02730364, NCT02678234
  13. Sep 19, 2016Phase 4 study in PainNCT02974114 · 21 enrolled · United Kingdom
  14. Jan 23, 2018Phase 1 study in Common ColdNCT03415243 · 28 enrolled · United States

TargetBeta

“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule

Studies

All 24 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03415243Common Cold · United States1CompletedMar 29, 201828
NCT02974114Pain · United Kingdom4TerminatedFeb 6, 201721
NCT02678234Respiratory Tract Infections3WithdrawnApr 1, 20170
NCT02730364Respiratory Tract Infections3WithdrawnApr 1, 20170
NCT02311881Pain · United States3CompletedFeb 2016960
NCT01842633Pain · United States3TerminatedMar 31, 2015365
NCT01822665Gastrointestinal Mucosal Damage · United States4CompletedJul 201228
NCT01767428Fever1CompletedApr 201030
NCT01686646Common Cold · United Kingdom3CompletedNov 2012240
NCT01551797Pain · United States1CompletedOct 201014
NCT01540734Healthy Subjects · United States1CompletedDec 200928
NCT01540721Healthy Subjects · United States1CompletedDec 200928
NCT01592227Pain · United States1CompletedDec 200930
NCT01476189Healthy Subjects · United States1CompletedDec 200928
NCT01466348Common Cold · United Kingdom4CompletedApr 201172
NCT01568749Agnosia · United States1CompletedAug 200914
NCT01551836Healthy Volunteer · United Kingdom1CompletedJun 200912
NCT01381640Healthy Subjects · United Kingdom1WithdrawnMay 20100
NCT01277081Common Cold · United Kingdom2CompletedDec 2010200
NCT01105936Osteoarthritis, Knee · Spain4CompletedAug 1, 201131
NCT01075243Toothache · United States4CompletedMar 2010401
NCT01082081Toothache · United States4CompletedMar 2010300
NCT00411190Osteoarthritis · Belgium1CompletedDec 15, 200632
NCT00370318Rotavirus Infections · Czech Republic3Completed400

How it is read

Names in the registry

  • “Acetaminophen”, 24 entries
  • “Paracetamol”, 10 entries
  • “IV Acetaminophen”, 10 entries
  • “Experimental paracetamol formulation”, 5 entries
  • “acetaminophen”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.